Mesenchymal stem cell‑derived extracellular vesicles promote the in vitro proliferation and migration of breast cancer cells through the activation of the ERK pathway

Zhou,Xiaohe; Li,Tao; Chen,Yufei; Zhang,Nannan; Wang,Pengli; Liang,Yingying; Long,Melissa; Liu,Haoran; Mao,Jian; Liu,Qiuyan; Sun,Xiaochun; Chen,Huabiao

doi:10.3892/ijo.2019.4747

Mesenchymal stem cell‑derived extracellular vesicles promote the in vitro proliferation and migration of breast cancer cells through the activation of the ERK pathway

Authors:
- Xiaohe Zhou
- Tao Li
- Yufei Chen
- Nannan Zhang
- Pengli Wang
- Yingying Liang
- Melissa Long
- Haoran Liu
- Jian Mao
- Qiuyan Liu
- Xiaochun Sun
- Huabiao Chen
View Affiliations

Affiliations: Jiangsu Key Laboratory of Clinical Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, Jiangsu 212013, P.R. China, Vaccine and Immunotherapy Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA, National Key Laboratory of Medical Immunology, Second Military Medical University, Shanghai 200433, P.R. China
Published online on: March 13, 2019 https://doi.org/10.3892/ijo.2019.4747
Pages: 1843-1852

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Mesenchymal stem cells (MSCs) have been demonstrated to be involved in tumor progression and the modulation of the tumor microenvironment, partly through their secretome. Extracellular vesicles (EVs) are membranous nanovesicles secreted by multiple types of cells and have been demonstrated to mediate intercellular communication in both physiological and pathological conditions. However, numerous questions still remain regarding the underlying mechanisms and functional consequences of these interactions. The purpose of this study was to investigate the effects of human umbilical cord mesenchymal stem cell‑derived EVs (hUC‑MSC‑EVs) on the proliferation, migration and invasion of human breast cancer cells. We successfully generated and identified hUC‑MSCs and hUC‑MSC‑EVs which were used in this study. The results revealed that treatment of the MDA‑MB‑231 and MCF‑7 human breast cancer cells with medium containing hUC‑MSC‑EVs significantly enhanced the proliferation, migration and invasion of the cells in vitro. Treatment of the cells with medium containing hUC‑MSC‑EVs also reduced E‑cadherin expression and increased N‑cadherin expression, thus promoting the epithelial‑mesenchymal transition (EMT) of the breast cancer cells. Treatment of the breast cancer cells with extracellular signal‑regulated kinase (ERK) inhibitor prior to the interaction with hUC‑MSC‑EVs significantly reversed the enhanced proliferation, migration and invasion, as well as the EMT of the breast cancer cells induced by the hUC‑MSC‑EVs. On the whole, these data indicate that hUC‑MSC‑EVs promote the invasive and migratory potential of breast cancer cells through the induction of EMT via the ERK pathway, leading to malignant tumor progression and metastasis. Taken together, the findings of this study suggest that targeting pathways to reverse EMT may lead to the development of novel therapeutic approaches with which to combat breast cancer.

View Figures

View References

1	Ruiz R, Herrero C, Strasser-Weippl K, Touya D, St. Louis J, Bukowski A and Goss PE: Epidemiology and pathophysiology of pregnancy-associated breast cancer: A review. Breast. 35:136–141. 2017.
2	Jhan JR and Andrechek ER: Effective personalized therapy for breast cancer based on predictions of cell signaling pathway activation from gene expression analysis. Oncogene. 36:3553–3561. 2017.
3	Korkaya H, Liu S and Wicha MS: Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest. 121:3804–3809. 2011.
4	Siegel RL, Miller KD and Jemal A: Cancer Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017.
5	Samavat H and Kurzer MS: Estrogen metabolism and breast cancer. Cancer Lett. 356:231–243. 2015.
6	Zhu A, Li Y, Song W, Xu Y, Yang F, Zhang W, Yin Y and Guan X: Antiproliferative effect of androgen receptor inhibition in mesenchymal stem-like triple-negative breast Cancer. Cell Physiol Biochem. 38:1003–1014. 2016.
7	Mao Y, Keller ET, Garfield DH, Shen K and Wang J: Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev. 32:303–315. 2013.
8	Li T, Zhang J, Zhang J, Zhang N, Zeng Y, Tang S, Tao Z, Qu X, Jia J, Zhu W, et al: Nicotine-enhanced stemness and epithelial-mesenchymal transition of human umbilical cord mesenchymal stem cells promote tumor formation and growth in nude mice. Oncotarget. 9:591–606. 2017.
9	Shang F, Liu S, Ming L, Tian R, Jin F, Ding Y, Zhang Y, Zhang H, Deng Z and Jin Y: Human umbilical cord MSCs as new cell sources for promoting periodontal regeneration in inflammatory periodontal defect. Theranostics. 7:4370–4382. 2017.
10	Song Y, Zhao HY, Lyu ZS, Cao XN, Shi MM, Wen Q, Tang FF, Wang Y, Xu LP, Zhang XH, et al: Dysfunctional bone marrow mesenchymal stem cells in patients with poor graft function after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 24:1981–1989. 2018.
11	Wang M, Song L, Strange C, Dong X and Wang H: Therapeutic effects of adipose stem cells from diabetic mice for the treatment of type 2 diabetes. Mol Ther. 26:1921–1930. 2018.
12	Uccelli A, Moretta L and Pistoia V: Mesenchymal stem cells in health and disease. Nat Rev Immunol. 8:726–736. 2008.
13	Mirzaei H, Sahebkar A, Avan A, Jaafari MR, Salehi R, Salehi H, Baharvand H, Rezaei A, Hadjati J, Pawelek JM, et al: Application of mesenchymal dtem cells in melanoma: A potential therapeutic strategy for delivery of targeted agents. Curr Med Chem. 23:455–463. 2016.
14	Wang Y, Chen X, Cao W and Shi Y: Plasticity of mesenchymal stem cells in immunomodulation: Pathological and therapeutic implications. Nat Immunol. 15:1009–1016. 2014.
15	Houthuijzen JM, Daenen LG, Roodhart JM and Voest EE: The role of mesenchymal stem cells in anti-cancer drug resistance and tumour progression. Br J Cancer. 106:1901–1906. 2012.
16	Guan J and Chen J: Mesenchymal stem cells in the tumor micro-environment. Biomed Rep. 1:517–521. 2013.
17	Kidd S, Spaeth E, Watson K, Burks J, Lu H, Klopp A, Andreeff M and Marini FC: Origins of the tumor microenvironment: Quantitative assessment of adipose-derived and bone marrow-derived stroma. PLoS One. 7:e305632012.
18	Deng J, Zou ZM, Zhou TL, Su YP, Ai GP, Wang JP, Xu H and Dong SW: Bone marrow mesenchymal stem cells can be mobilized into peripheral blood by G-CSF in vivo and integrate into traumatically injured cerebral tissue. Neurol Sci. 32:641–651. 2011.
19	Kidd S, Spaeth E, Dembinski JL, Dietrich M, Watson K, Klopp A, Battula VL, Weil M, Andreeff M and Marini FC: Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells. 27:2614–2623. 2009.
20	Roorda BD, ter Elst A, Kamps WA and de Bont ES: Bone marrow-derived cells and tumor growth: Contribution of bone marrow-derived cells to tumor micro-environments with special focus on mesenchymal stem cells. Crit Rev Oncol Hematol. 69:187–198. 2009.
21	Li T, Zhang C, Ding Y, Zhai W, Liu K, Bu F, Tu T, Sun L, Zhu W, Zhou F, et al: Umbilical cord-derived mesenchymal stem cells promote proliferation and migration in MCF-7 and MDA-MB-231 breast cancer cells through activation of the ERK pathway. Oncol Rep. 34:1469–1477. 2015.
22	Nawaz M, Fatima F, Vallabhaneni KC, Penfornis P, Valadi H, Ekström K, Kholia S, Whitt JD, Fernandes JD, Pochampally R, et al: Extracellular vesicles: Evolving factors in stem cell biology. Stem Cells Int. 2016:10731402016.
23	Rani S, Ryan AE, Griffin MD and Ritter T: Mesenchymal stem cell-derived extracellular vesicles: Toward cell-free therapeutic applications. Mol Ther. 23:812–823. 2015.
24	Zhang Y, Chopp M, Meng Y, Katakowski M, Xin H, Mahmood A and Xiong Y: Effect of exosomes derived from multipluri-potent mesenchymal stromal cells on functional recovery and neurovascular plasticity in rats after traumatic brain injury. J Neurosurg. 122:856–867. 2015.
25	Gangadaran P, Hong CM and Ahn BC: Current perspectives on in vivo noninvasive tracking of extracellular vesicles with molecular imaging. BioMed Res Int. 2017:91583192017.
26	EL Andaloussi S, Mäger I, Breakefield XO and Wood MJ: Extracellular vesicles: Biology and emerging therapeutic opportunities. Nat Rev Drug Discov. 12:347–357. 2013.
27	Fong MY, Zhou W, Liu L, Alontaga AY, Chandra M, Ashby J, Chow A, O’Connor ST, Li S, Chin AR, et al: Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Nat Cell Biol. 17:183–194. 2015.
28	Goldie BJ, Dun MD, Lin M, Smith ND, Verrills NM, Dayas CV and Cairns MJ: Activity-associated miRNA are packaged in Map1b-enriched exosomes released from depolarized neurons. Nucleic Acids Res. 42:9195–9208. 2014.
29	Crescitelli R, Lässer C, Szabó TG, Kittel A, Eldh M, Dianzani I, Buzás EI and Lötvall J: Distinct RNA profiles in subpopulations of extracellular vesicles: Apoptotic bodies, microvesicles and exosomes. J Extracell Vesicles. 2:22013.
30	Peng J, Wang W, Hua S and Liu L: Roles of extracellular vesicles in metastatic breast cancer. Breast Cancer (Auckl). Apr 25–2018.Epub ahead of print. View Article : Google Scholar
31	Gu Y, Li T, Ding Y, Sun L, Tu T, Zhu W, Hu J and Sun X: Changes in mesenchymal stem cells following long-term culture in vitro. Mol Med Rep. 13:5207–5215. 2016.
32	Gould CM and Courtneidge SA: Regulation of invadopodia by the tumor microenvironment. Cell Adhes Migr. 8:226–235. 2014.
33	Sun Z, Wang S and Zhao RC: The roles of mesenchymal stem cells in tumor inflammatory microenvironment. J Hematol Oncol. 7:142014.
34	Lai RC, Yeo RW and Lim SK: Mesenchymal stem cell exosomes. Semin Cell Dev Biol. 40:82–88. 2015.
35	Ramdasi S, Sarang S and Viswanathan C: Potential of mesenchymal stem cell based application in cancer. Int J Hematol Oncol Stem Cell Res. 9:95–103. 2015.
36	Ji R, Zhang B, Zhang X, Xue J, Yuan X, Yan Y, Wang M, Zhu W, Qian H and Xu W: Exosomes derived from human mesenchymal stem cells confer drug resistance in gastric cancer. Cell Cycle. 14:2473–2483. 2015.
37	Stenderup K, Justesen J, Clausen C and Kassem M: Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone. 33:919–926. 2003.
38	Rao MS and Mattson MP: Stem cells and aging: Expanding the possibilities. Mech Ageing Dev. 122:713–734. 2001.
39	Troyer DL and Weiss ML: Wharton’s jelly-derived cells are a primitive stromal cell population. Stem Cells. 26:591–599. 2008.
40	Secco M, Zucconi E, Vieira NM, Fogaça LL, Cerqueira A, Carvalho MD, Jazedje T, Okamoto OK, Muotri AR and Zatz M: Multipotent stem cells from umbilical cord: Cord is richer than blood. Stem Cells. 26:146–150. 2008.
41	Yu PF, Huang Y, Han YY, Lin LY, Sun WH, Rabson AB, Wang Y and Shi YF: TNFα-activated mesenchymal stromal cells promote breast cancer metastasis by recruiting CXCR2⁺ neutrophils. Oncogene. 36:482–490. 2017.
42	Coffman LG, Choi YJ, McLean K, Allen BL, di Magliano MP and Buckanovich RJ: Human carcinoma-associated mesenchymal stem cells promote ovarian cancer chemotherapy resistance via a BMP4/HH signaling loop. Oncotarget. 7:6916–6932. 2016.
43	Dong L, Pu Y, Zhang L, Qi Q, Xu L, Li W, Wei C, Wang X, Zhou S, Zhu J, et al: Human umbilical cord mesenchymal stem cell-derived extracellular vesicles promote lung adenocarcinoma growth by transferring miR-410. Cell Death Dis. 9:2182018.
44	Wu XB, Liu Y, Wang GH, Xu X, Cai Y, Wang HY, Li YQ, Meng HF, Dai F and Jin JD: Mesenchymal stem cells promote colorectal cancer progression through AMPK/mTOR-mediated NF-κB activation. Sci Rep. 6:214202016.
45	Kim SH, Bang SH, Kang SY, Park KD, Eom JH, Oh IU, Yoo SH, Kim CW and Baek SY: Human amniotic membrane-derived stromal cells (hAMSC) interact depending on breast cancer cell type through secreted molecules. Tissue Cell. 47:10–16. 2015.
46	Marofi F, Vahedi G, Biglari A, Esmaeilzadeh A and Athari SS: Mesenchymal stromal/stem cells: A new era in the cell-based targeted gene therapy of cancer. Front Immunol. 8:17702017.
47	Song N, Gao L, Qiu H, Huang C, Cheng H, Zhou H, Lv S, Chen L and Wang J: Mouse bone marrow-derived mesenchymal stem cells inhibit leukemia/lymphoma cell proliferation in vitro and in a mouse model of allogeneic bone marrow transplant. Int J Mol Med. 36:139–149. 2015.
48	Yulyana Y, Ho IA, Sia KC, Newman JP, Toh XY, Endaya BB, Chan JK, Gnecchi M, Huynh H, Chung AY, et al: Paracrine factors of human fetal MSCs inhibit liver cancer growth through reduced activation of IGF-1R/PI3K/Akt signaling. Mol Ther. 23:746–756. 2015.
49	Klopp AH, Gupta A, Spaeth E, Andreeff M and Marini F III: Concise review: Dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth? Stem Cells. 29:11–19. 2011.
50	Melzer C, Yang Y and Hass R: Interaction of MSC with tumor cells. Cell Commun Signal. 14:202016.
51	Chin AR and Wang SE: Cancer-derived extracellular vesicles: The ‘soil conditioner’ in breast cancer metastasis? Cancer Metastasis Rev. 35:669–676. 2016.
52	He C, Zheng S, Luo Y and Wang B: Exosome theranostics: Biology and translational medicine. Theranostics. 8:237–255. 2018.
53	Ridge SM, Sullivan FJ and Glynn SA: Mesenchymal stem cells: Key players in cancer progression. Mol Cancer. 16:312017.
54	Yang H, Zhang H, Ge S, Ning T, Bai M, Li J, Li S, Sun W, Deng T, Zhang L, et al: Exosome-derived miR-130a activates angiogenesis in gastric cancer by targeting C-MYB in vascular endothelial cells. Mol Ther. 26:2466–2475. 2018.
55	Colombo M, Raposo G and Théry C: Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 30:255–289. 2014.
56	Xu R, Greening DW, Zhu HJ, Takahashi N and Simpson RJ: Extracellular vesicle isolation and characterization: Toward clinical application. J Clin Invest. 126:1152–1162. 2016.
57	Platanias LC: Map kinase signaling pathways and hematologic malignancies. Blood. 101:4667–4679. 2003.
58	Xiao J, Yang S, Shen P, Wang Y, Sun H, Ji F and Zhou D: Phosphorylation of ETV4 at Ser73 by ERK kinase could block ETV4 ubiquitination degradation in colorectal cancer. Biochem Biophys Res Commun. 486:1062–1068. 2017.
59	Jia S, Lu J, Qu T, Feng Y, Wang X, Liu C and Ji J: MAGI1 inhibits migration and invasion via blocking MAPK/ERK signaling pathway in gastric cancer. Chin J Cancer Res. 29:25–35. 2017.
60	Talbot LJ, Bhattacharya SD and Kuo PC: Epithelial-mesenchymal transition, the tumor microenvironment, and metastatic behavior of epithelial malignancies. Int J Biochem Mol Biol. 3:117–136. 2012.